- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2018–2024 · career development · K00
Investigating molecular mechanism of immune response during cancer progression
Zeyu Chen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2025 · research · R37
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Andrew A Lane · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Novel therapeutic approaches with CDK4/6 inhibitors for melanoma treatment
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · fellowship · F32
The molecular basis of substrate specificity for a small molecule ubiquitin ligase complex
Tyler B Faust · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · research · R01
KDM5 histone lysine demethylases as potential novel myeloid tumor suppressors
Julie-Aurore Losman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · fellowship · F32
The molecular basis of substrate specificity for a small molecule ubiquitin ligase complex
Tyler B Faust · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2027 · research · R01
Advanced computational methods in analyzing high-throughput sequencing data
Heng Li · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2019 · fellowship · F31
The Discovery and Optimization of Alternatives to ATP-Competitive ALK Inhibitors
Chelsea Elizabeth Powell · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R37
Molecular origins and evolution to chemoresistance in germ cell tumors
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018 · award
Obesity, Molecular Biomarkers, and Multiple Myeloma Prognosis
Catherine Marinac · Dana-Farber Cancer Institute · funded by American Cancer Society
2018–2019 · fellowship · CIHR Fellowship
Targeting acquired resistance to oncogenic KRAS inhibition in Pancreatic cancer models using quantitative chemoproteomics
Amrita Singh Chandhoke · Dana-Farber Cancer Institute · funded by Canadian Institutes of Health Research
2018–2023 · research · R01
Novel therapeutic approaches with CDK4/6 inhibitors for melanoma treatment
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R37
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Andrew A Lane · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2025 · research · R01
Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition
Patrick Alexander Ott · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · research · R00
Characterizing the resistance mechanisms to BET-bromodomain inhibition in MYC-amplified medulloblastoma
Pratiti Bandopadhayay · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · program · P20
Precision Interception of Aggressive Prostate Cancer in African American Men
Timothy R Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
(PQ3) A functional genomic approach to identification and interpretation of germline-tumor genetic interactions
Alexander Gusev · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U01
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
Lawrence Fong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2020 · career development · K08
Investigating the Mechanisms of Cohesinopathy in Myelodysplastic Syndromes
Zuzana Tothova · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · research · R01
Advanced computational methods in analyzing high-throughput sequencing data
Heng Li · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U01
Rewiring of regulatory networks in breast cancer by transcription factor isoforms
Martha L Bulyk · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Comprehensive minimal residual disease tracking in cancer
G. Mike Makrigiorgos · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · career development · K08
Targeting casein kinase 1-alpha for cancer therapy
Steven Muntean Corsello · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · research · R01
Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma
Rochelle Bagatell · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018 · grant · Lung Cancer Research Foundation Annual Grant Program
2018 – Lung Cancer Research Foundation Annual Grant Program – Dana-Farber Cancer Institute – Israel Cañadas Castillo, PhD
Israel Cañadas Castillo · Dana-Farber Cancer Institute · funded by Lung Cancer Research Foundation
2018 · research
Developing new therapeutic strategies for breast and gynecologic cancers
Panagiotis Konstantinopoulos · Dana-Farber Cancer Institute · funded by Breast Cancer Research Foundation
2018 · career development · Career Development Award
PELOPS: Palbociclib and Endocrine therapy for LObular breast cancer Preoperative Study: A randomized phase II study of Palbociclib with endocrine therapy versus endocrine therapy alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma
Otto Metzger · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2018 · career development · Young Investigator Award
Exploring Retinoblastoma-Dependent Mechanisms of Resistance to Cyclin-Dependent Kinase Inhibitors in Metastatic, Hormone-Receptor Positive Breast Cancer
Seth Wander · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2018 · career development · Young Investigator Award
Evaluating the immune landscape of metastatic triple-negative breast cancer and identifying predictive biomarkers of response to PD-1 inhibition
Ana Garrido-Castro · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2018 · fellowship · QuadW Foundation-AACR Fellowship for Clinical/Translational Sarcoma Research
Novel drug combinations with CDK4/6 inhibitors in Ewing sarcoma
Lillian M. Guenther · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2018 · fellowship · ASH Research Training Award for Fellows (RTAF): Junior Awardees
ASH Research Training Award for Fellows (RTAF) 2018: Reid Merryman
Reid Merryman · Dana-Farber Cancer Institute · funded by American Society of Hematology
2018 · career development · Young Investigator Award
Radiation therapy in immune checkpoint inhibitor resistant head and neck cancer
Devarati Mitra · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2018 · career development · Young Investigator Award
A Phase II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Jennifer Crombie · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2018 · career development · Young Investigator Award
Identifying therapeutic dependencies in PPM1D-mutated diffuse intrinsic pontine glioma
Zachary Reitman · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2018 · career development · Career Development Award
Metabolomic characterization of PD1 blockade in renal cell carcinoma
Marios Giannakis · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2018 · career development · Global Oncology Young Investigator Award
Novel Diagnostics for Lymphoma in Guatemala
Edward Briercheck · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2018 · career development · Young Investigator Award
Evaluation of ctDNA as a prognostic biomarker in patients with localized Ewing sarcoma
David Shulman · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2018–2025 · research · PANCREATIC CANCER COLLECTIVE RESEARCH TEAM — NEW THERAPIES CHALLENGE
Exploiting DNA Repair Gene Mutations in Pancreatic Cancer
Alan D. D’Andrea · Dana-Farber Cancer Institute · funded by Stand Up To Cancer
2018 · career development · Young Investigator Award
Effect of EZH2 Inhibition on De-Repression of Endogenous Retroviruses and Response to PD-1 Blockade in Melanoma
Russell Jenkins · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2018 · research · AACR-The Mark Foundation NextGen Grant for Transformative Cancer Research
Epigenetic heterogeneity as a modulator of therapeutic response in T-ALL
Birgit Knoechel · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
